Mints, nice one! It is good to have such an especially transparent and braindead basher around. Was it worth it to sell your rat soul to wall street for $2/hour?
Often times stupid people don't know they're stupid.
I did not know that this small study, 10 people for 30 days, was occuring.
Improvements in 70% of patients within 30 days.
Here is the info on the double blind trial already ongoing,
A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc Crème in Rosacea
Estimated Enrollment: 120
Study Start Date: November 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013
This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.
Primary Outcome Measures: (Time Frame: 8 weeks) Collected information of the safety, tolerability and adverse events, and subjective experience related to the use of Anatabloc Cream by subjects
Secondary Outcome Measures: (Time Frame: 8 weeks) Change in the appearance of the facial skin
I guess they are considering that the tail risk is low enough that they can short the calls.
By shorting or naked shorting while selling the calls, they satisfy certain less sophisticated volatility models, in other words, they are manipulating the stock lower since they think it is less likely for the stock to recover. This might mean Shorty is smarter than the MM, IF that is what's happening.
It could be that shorty and the MM are in bed together, and shorty knows that the only way to short more right now in a manipulation tactic is for the MM to naked short for him.
The failstodeliver website indicates that they were covering naked shorted shares at $3 last year, AFTER the stock bounced hard tobacco lawsuit settlement.
In July they shorted 800k shares into the uptrend at 1.50, only to cover 1.5M shares in the 2nd half of July at 1.90.
Shorty is nauseous and holding a gun to his own head every day. The recent shorting is a desperate tactic to shake shares away from weak hands.
Sentiment: Strong Buy
What about Veterans affairs, I wonder if that is based on a specific research proposal? It appears to be.
See ihub post 15208
See ihub post 15208
Between 6/30 and 9/30:
Share price went from about 1.39 to 1.91
Shorts covered 4.0 million shares
47 Increased Institutional Holders
4,348,952 Increased Total Shares Held
35 Decreased Institutional Holders
613,830 Decreased Total Shares Held
The shorts shorted 840k shares at the cheapest July prices (first half of the month), then covered 1.8million shares at the most expensive July prices (2nd half of the month).
If they can get criminal articles into Bloomberg, they can get a $2/hour cockroach a moderator position at an investment message board.
Some relevant snippets from the FDA website... like Izof said, google fda dietary supplement claims guidelines to learn more.
Star can and already does claim certain things about Anatabloc the supplement, and next up will be "Qualified Health Claims". Eventually, "Health Claims" about specific conditions, with fewer disclaimers.
What is a health claim?
A health claim is an explicit or implied characterization of a relationship between a substance and a disease or a health-related condition. This type of claim requires significant scientific agreement and must be authorized by FDA.
How is a health claim different from a structure/function claim?
A health claim describes the effect a substance has on reducing the risk of or preventing a disease, e.g., "calcium may reduce the risk of osteoporosis." A health claim requires FDA evaluation and authorization prior to its use. A structure/function claim describes the role of a substance intended to maintain the structure or function of the body. Structure/function claims do not require preapproval by FDA.
What is a qualified health claim?
A qualified health claim is supported by less scientific evidence than an authorized health claim. FDA requires that qualified claims be accompanied by a disclaimer that explains the level of the scientific evidence supporting the relationship.
Unlike authorized health claims, FDA does not issue regulations for qualified health claims.
What types of structure/functure claims may be made under section 403(r)(6) of the act?
... A statement that claims a benefit related to a classical nutrient deficiency disease and that discloses the prevalence of such disease in the U.S.;
Sentiment: Strong Buy
They are working harder on STSI than they are on any other stock. Maybe it has to do with the 2,000% losses they face if they try to cover 28 million shares?
This is for Trade Dates from APPROXIMATELY 10/10 to 10/28, during which time the stock price went from about 1.97 to 1.90.
No big change in price or short interest on net.
I hereby nominate carlcimini for the Pulitzer prize for this headline
Meanwhile the Star Scientific CEO is in the running for the 2016 Nobel Prize in Medicine for his unprecedented, effective treatment for dozens of autoimmune disorders and cancer prevention
From the journal:
"Early Release articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance, on a weekly basis, before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Early Release manuscripts and the final, typeset articles. The manuscripts remain listed on the Early Release page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Early Release page. "
I'm not an expert but I don't see why there would be any huge changes when the final version is out.